DE69927147D1 - Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen - Google Patents

Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen

Info

Publication number
DE69927147D1
DE69927147D1 DE69927147T DE69927147T DE69927147D1 DE 69927147 D1 DE69927147 D1 DE 69927147D1 DE 69927147 T DE69927147 T DE 69927147T DE 69927147 T DE69927147 T DE 69927147T DE 69927147 D1 DE69927147 D1 DE 69927147D1
Authority
DE
Germany
Prior art keywords
osteoprotegerin
prevention
treatment
cardiovascular diseases
opg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927147T
Other languages
English (en)
Other versions
DE69927147T2 (de
Inventor
Scott Simonet
Ildiko Sarosi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69927147D1 publication Critical patent/DE69927147D1/de
Application granted granted Critical
Publication of DE69927147T2 publication Critical patent/DE69927147T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69927147T 1998-04-23 1999-04-21 Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen Expired - Lifetime DE69927147T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64832 1998-04-23
US09/064,832 US6790823B1 (en) 1998-04-23 1998-04-23 Compositions and methods for the prevention and treatment of cardiovascular diseases
PCT/US1999/008793 WO1999053942A1 (en) 1998-04-23 1999-04-21 Compositions comprising osteoprotegerin for the prevention and treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
DE69927147D1 true DE69927147D1 (de) 2005-10-13
DE69927147T2 DE69927147T2 (de) 2006-01-26

Family

ID=22058524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69927147T Expired - Lifetime DE69927147T2 (de) 1998-04-23 1999-04-21 Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen

Country Status (11)

Country Link
US (1) US6790823B1 (de)
EP (1) EP1073456B1 (de)
JP (1) JP4776774B2 (de)
AT (1) ATE303817T1 (de)
AU (1) AU757806B2 (de)
CA (1) CA2325360C (de)
DE (1) DE69927147T2 (de)
DK (1) DK1073456T3 (de)
ES (1) ES2248998T3 (de)
SI (1) SI1073456T1 (de)
WO (1) WO1999053942A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
JP4138013B2 (ja) 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ｔｎｆスーパーファミリーのメンバーであるｎｆ−ｋａｐｐａ ｂの受容体アクティベーターに対するリガンド
HU229476B1 (en) 1997-04-15 2014-01-28 Daiichi Sankyo Company Antibodies against obm
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
ATE417068T1 (de) * 1998-04-23 2008-12-15 Ajinomoto Kk Stoff mit antithrombotischer aktivität und verfahren zur bestimmung von glycokallidin
EP1076699B1 (de) 1998-05-14 2008-10-29 Immunex Corporation Verfahren zur hemmung der wirkung der osteoklasten
JP4921687B2 (ja) * 2001-04-03 2012-04-25 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 乳中の破骨細胞分化抑制因子
US7198798B2 (en) * 2001-05-10 2007-04-03 University Of Washington Methods and devices for promoting endothelial morphogenesis
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US8649843B2 (en) * 2001-11-24 2014-02-11 Ben A. Arnold Automated calcium scoring of the aorta
EP1494714A4 (de) 2002-04-05 2008-03-05 Amgen Inc Humane anti-opgl-neutralisierende antikörper als selektive opgl-pfad-hemmer
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
EP1515743A2 (de) 2002-04-10 2005-03-23 Applied Research Systems ARS Holding N.V. Verwendung von osteoprotegerin zur vorbeugung gegen und behandlung von fibrose/sklerose
EP2502941A1 (de) 2004-10-25 2012-09-26 Intezyne Technologies Inc. Heterobifunktionelles Poly(ethylenglykol) und seine Verwendungen
NZ598887A (en) 2005-01-04 2013-06-28 Intezyne Technologies Inc A method for preparing a multi-block copolymer
US7561727B2 (en) * 2005-06-02 2009-07-14 Nordic Bioscience Imaging A/S Method of deriving a quantitative measure of a degree of calcification of an aorta
US7463758B2 (en) * 2005-06-02 2008-12-09 Nordio Bioscience A/S Method of deriving a quantitative measure of a degree of calcification of an aorta
EP2433644A1 (de) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Brustkrebstherapeutika
FR2970870A1 (fr) * 2011-01-31 2012-08-03 Centre Nat Rech Scient Modulation de la proliferation des cellules epitheliales de l'unite epidermo-pilo-sebacee via rank

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin

Also Published As

Publication number Publication date
US6790823B1 (en) 2004-09-14
WO1999053942A8 (en) 1999-12-02
JP4776774B2 (ja) 2011-09-21
DE69927147T2 (de) 2006-01-26
EP1073456B1 (de) 2005-09-07
EP1073456A1 (de) 2001-02-07
ES2248998T3 (es) 2006-03-16
DK1073456T3 (da) 2005-10-24
WO1999053942A1 (en) 1999-10-28
CA2325360A1 (en) 1999-10-28
AU757806B2 (en) 2003-03-06
SI1073456T1 (sl) 2005-12-31
ATE303817T1 (de) 2005-09-15
JP2002512199A (ja) 2002-04-23
CA2325360C (en) 2008-11-04
AU3660599A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
DE69927147D1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69802260D1 (de) Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE319453T1 (de) Reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE293883T1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
ATE265857T1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
ATE236870T1 (de) Substituierte 2-phenyl-1-(3,4-dihydroxy-5- nitrophenyl)-1-ethanone, deren verwendung zur behandlung von erkrankungen des zentralen und periphären nervensystems und diese enthaltende pharmazeutische zusammensetzungen
ID28460A (id) Komposisi dan metoda untuk perlakuan dan pencegahan penyakit tulang dengan menggunakan tocotrienol
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ID28894A (id) Metoda dan komposisi untuk perlakuan terhadap penyakit gangguan gastro-esophageal
TR200200278T2 (tr) Kalsilitik bileşimler
DE69713571D1 (de) Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition